Aphria Inc. (NYSE: APHA) is one of the largest cannabis companies in the world, with a stock market capitalization of over $2.46 billion. The company has production capacity of more than 255,000kg of cannabis product per year. It has supply agreements in provinces throughout Canada, with medical access to 99% of the Canadian population.
Like many of the strongest cannabis companies, revenue has grown consistently in the last five years. In the 2018 fiscal year, revenue increased 80.62%, with gross income jumping 19.26% in the same period. Investors have put a lot of confidence in this stock in the last three months, with share price increasing by 75% in 2019.
Long term, the company’s production capacity keeps it primed for growth.
It is the market leading brand for Canadian patients seeking medical cannabis treatment. Recent expansion with CBD products in Germany will also boost the bottom line. Analysts believe the Canada’s recent legalization of recreational marijuana will create growth opportunities for Aphria. The average analyst target for 2019 gives a projected share price peak of $15.98, suggesting a strong return even for investors who are only willing to stay in this stock for the mid-term.
- 1 Year Price Growth: 84%
- YTD Price Growth: 99%
- 3 Month Price Growth: 91%
All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.